Actively Recruiting
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
Led by Varian, a Siemens Healthineers Company · Updated on 2026-02-05
132
Participants Needed
7
Research Sites
428 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.
CONDITIONS
Official Title
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male patients aged 18 years or older
- Biopsy-proven low or intermediate risk prostate cancer as defined by NCCN
- Prostate volume less than or equal to 80cc as measured by MRI before radiotherapy
- AUA/IPSS urinary symptom score of 15 or less
- ECOG performance status of 2 or less (or Karnofsky score of 60% or higher)
- No PIRADS 4 or 5 lesion on prostate MRI contacting the urethra, as determined by physician
- Ability to complete required patient questionnaires
- Ability to understand and willingness to sign informed consent
You will not qualify if you...
- Baseline grade 3 or higher gastrointestinal or genitourinary toxicity
- Prior overlapping pelvic radiotherapy
- History of transurethral resection of the prostate, prostate HIFU, or cryoablation
- Node positive prostate cancer
- Presence of extracapsular extension (capsular abutment is allowed)
- Active inflammatory bowel disease or active collagen vascular disease
- Inability to undergo prostate MRI
- Inability to undergo prostate fiducial marker placement
- Currently receiving cytotoxic chemotherapy (androgen deprivation therapy is allowed)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Duarte Cancer Center
Duarte, California, United States, 91010
Actively Recruiting
2
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California, United States, 92618
Actively Recruiting
3
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Active, Not Recruiting
4
Washington University in St. Louis
St Louis, Missouri, United States, 63110
Actively Recruiting
5
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Active, Not Recruiting
6
Universitätsklinikum des Saarlandes (Saarland Univerisity Hospital)
Homburg, Saarland, Germany, 66421
Actively Recruiting
7
Hospital Universitario de Navarra
Pamplona, Navarre, Spain, 31008
Actively Recruiting
Research Team
S
Sean Davidson, MASc
CONTACT
C
Claire McCann, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here